ALNY Alnylam Pharmaceuticals, Inc

Price (delayed)

$125.66

Market cap

$14.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.84

Enterprise value

$14.43B

Sector: Healthcare
Industry: Biotechnology
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Highlights

The company's revenue has surged by 137% YoY and by 16% QoQ
The gross profit has soared by 116% YoY and by 13% from the previous quarter
The equity has contracted by 24% YoY and by 13% from the previous quarter
The company's quick ratio fell by 23% QoQ and by 21% YoY

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
116.18M
Market cap
$14.6B
Enterprise value
$14.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.99
Price to sales (P/S)
36.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.99
Earnings
Revenue
$400.97M
EBIT
-$832.61M
EBITDA
-$764.29M
Free cash flow
-$775.3M
Per share
EPS
-$7.84
Free cash flow per share
-$6.68
Book value per share
$10.48
Revenue per share
$3.46
TBVPS
$28.51
Balance sheet
Total assets
$3.31B
Total liabilities
$2.09B
Debt
$329.45M
Equity
$1.22B
Working capital
$2.07B
Liquidity
Debt to equity
0.27
Current ratio
5.32
Quick ratio
3.98
Net debt/EBITDA
0.22
Margins
EBITDA margin
-190.6%
Gross margin
83.2%
Net margin
-222.2%
Operating margin
-232.5%
Efficiency
Return on assets
-31.4%
Return on equity
-66%
Return on invested capital
-37.2%
Return on capital employed
-29.5%
Return on sales
-207.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
2.15%
1 week
-2.82%
1 month
-4.69%
1 year
17.54%
YTD
9.11%
QTD
-13.7%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$400.97M
Gross profit
$333.77M
Operating income
-$932.29M
Net income
-$890.93M
Gross margin
83.2%
Net margin
-222.2%
The company's revenue has surged by 137% YoY and by 16% QoQ
The gross profit has soared by 116% YoY and by 13% from the previous quarter
The company's operating margin has surged by 54% YoY and by 13% QoQ
The net margin has soared by 54% YoY and by 9% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
11.99
P/S
36.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.99
ALNY's EPS is down by 3.4% since the previous quarter
ALNY's price to book (P/B) is 74% more than its 5-year quarterly average of 6.9 and 9% more than its last 4 quarters average of 11.0
The equity has contracted by 24% YoY and by 13% from the previous quarter
The company's revenue has surged by 137% YoY and by 16% QoQ
ALNY's price to sales (P/S) is 65% lower than its 5-year quarterly average of 103.4 and 24% lower than its last 4 quarters average of 47.9

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 57% year-on-year and by 12% since the previous quarter
ALNY's return on invested capital is up by 36% year-on-year and by 11% since the previous quarter
The ROE has contracted by 25% YoY and by 13% from the previous quarter
The return on assets has increased by 15% year-on-year

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 58% more than the total liabilities
The company's total liabilities has surged by 124% YoY and by 6% QoQ
The company's quick ratio fell by 23% QoQ and by 21% YoY
The debt is 73% less than the equity
Alnylam Pharmaceuticals's debt to equity has increased by 42% YoY and by 17% from the previous quarter
The equity has contracted by 24% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.